Trials / Completed
CompletedNCT03353740
Gallium-68 PSMA-11 Positron Emission Tomography (PET) Imaging in Patients With Biochemical Recurrence
Gallium-68 PSMA-11 PET Imaging in Patients With Biochemical Recurrence
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 346 (actual)
- Sponsor
- Thomas Hope · Academic / Other
- Sex
- Male
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The investigators are imaging patients with prostate cancer using a new PET imaging agent (Ga-68-PSMA-11) in order to evaluate its ability to detection prostate cancer in patients with biochemical recurrence after prostatectomy and radiation therapy.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Ga-68 labeled PSMA-11 PET | Patients will be imaged using Ga-68 labeled PSMA-11 PET to determine if the presence of metastatic disease. Prostate Specific Membrane Antigen (PSMA) is a protein expressed on prostate cancer cells that can be imaged using small molecules that target this protocol. |
Timeline
- Start date
- 2017-09-20
- Primary completion
- 2020-09-01
- Completion
- 2020-09-01
- First posted
- 2017-11-27
- Last updated
- 2021-10-21
- Results posted
- 2021-10-21
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03353740. Inclusion in this directory is not an endorsement.